Cited by 323Cancer Immunotherapy and BiomarkersImmune cells in cancerFerroptosis and cancer prognosis

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy

Open access

Liu, Yuting, Zugazagoitia, Jon, Ahmed, Fahad Shabbir, Henick, Brian S., Gettinger, Scott N., Herbst, Roy S., Schalper, Kurt A., Rimm, David L.·2020·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-19-1040PMC PMC7024671

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: Programmed death ligand 1 (PD-L1) is expressed in tumor cells and immune cells, and both have been associated with response to anti-PD-1 axis immunotherapy. Here, we examine the expression of PD-L1 to determine which cell type carries the predictive value of the test. Experimental Design: We measured the expression of PD-L1 in multiple immune cells with two platforms and confocal microscopy on three retrospective Yale NSCLC cohorts (425 nonimmunotherapy-treated cases and 62 pembrolizumab/nivolumab/atezolizumab-treated cases). The PD-L1 level was selectively measured in different immune cell subsets using two multiplexed quantitative immunofluorescence panels, including CD56 for natural killer cells, CD68 for macrophages, and CD8 for cytotoxic T cells. Results: PD-L1 was significantly higher in macrophages in both tumor and stromal compartment compared with other immune cells. Elevated PD-L1 in macrophages was correlated with high PD-L1 level in tumor as well as CD8 and CD68 level (P < 0.0001). High PD-L1 expression in macrophages was correlated with better overall survival (OS; P = 0.036 by cell count/P = 0.019 by molecular colocalization), while high PD-L1 expression in tumor cells was not. Conclusions: In nearly 500 non–small cell lung cancer (NSCLC) cases, the predominant immune cell type that expresses PD-L1 is CD68+ macrophages. The level of PD-L1 in macrophages is significantly associated with the level of PD-L1 in tumor cells and infiltration by CD8+ T cells, suggesting a connection between high PD-L1 and “hot” tumors. In anti-PD-1 axis therapy–treated patients, high levels of PD-L1 expression in macrophages are associated with longer OS and may be responsible for the predictive effect of the marker.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-1040

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citation
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,559
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314

Show all 34 references

Sorted by citations

PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Self-citation
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.001 · Cited by 1,192
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 909
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Petitprez, F., Meylan, M., de Reyniès, A., Sautès‐Fridman, C., & Fridman, W. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00784 · Cited by 621
The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis
Li, F., Li, C., Cai, X., Xie, Z., Zhou, L., Cheng, B., Zhong, R., Xiong, S., Li, J., Chen, Z., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101134 · Cited by 376
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
Ho, W. J., Zhu, Q., Durham, J., Popovic, A., Xavier, S., Leatherman, J., Mohan, A., Mo, G., Zhang, S., Gross, N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00234-4 · Cited by 360
Understanding the tumor microenvironment for effective immunotherapy
Sadeghi Rad, H., Monkman, J., Warkiani, M. E., Ladwa, R., O'Byrne, K., Rezaei, N., & Kulasinghe, A. (2021) · Medicinal Research Reviews · doi:10.1002/med.21765 · Cited by 334
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
Genova, C., Dellepiane, C., Carrega, P., Sommariva, S., Ferlazzo, G., Pronzato, P., Gangemi, R. M. R., Filaci, G., Coco, S., & Croce, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.799455 · Cited by 273
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Grant, M. J., Herbst, R. S., & Goldberg, S. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00520-1 · Cited by 257
Self-citation
Colorectal Cancer‐Derived Small Extracellular Vesicles Promote Tumor Immune Evasion by Upregulating PD‐L1 Expression in Tumor‐Associated Macrophages
Yin, Y., Liu, B., Cao, Y., Yao, S., Liu, Y., Jin, G., Yan, Q., Chen, Y., Cui, K., Zhou, L., et al. (2022) · Advanced Science · doi:10.1002/advs.202102620 · Cited by 249
Self-citation
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice
Ericsson, P. I. G., Stovgaard, E. S., Sua, L. F., Reisenbichler, E., Kos, Z., Carter, J. M., Michiels, S., Quesne, J. P. C. L., Nielsen, T. O., Lænkholm, A., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5406 · Cited by 215
Self-citation
Glial and myeloid heterogeneity in the brain tumour microenvironment
Andersen, B. M., Akl, C. F., Wheeler, M. A., Chiocca, E. A., Reardon, D. A., & Quintana, F. J. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00397-3 · Cited by 216
A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications
Sedighzadeh, S. S., Khoshbin, A. P., Razi, S., Keshavarz‐Fathi, M., & Rezaei, N. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1241 · Cited by 190
Spatially Segregated Macrophage Populations Predict Distinct Outcomes in Colon Cancer
Matusiak, M., Hickey, J. W., van IJzendoorn, D. G. P., Lu, G., Kidziński, Ł., Zhu, S., Colburg, D. R. C., Luca, B. A., Phillips, D. J., Brubaker, S. W., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1300 · Cited by 190
Linking macrophage metabolism to function in the tumor microenvironment
Jin, R., Neufeld, L. A., & McGaha, T. L. (2025) · Nature Cancer · doi:10.1038/s43018-025-00909-2 · Cited by 183
Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy
Li, W., Wu, F., Zhao, S., Shi, P., Wang, S., & Cui, D. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.004 · Cited by 161
Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment
Fjæstad, K. Y., Rømer, A. M. A., Goitea, V. E., Johansen, A. Z., Thorseth, M., Carretta, M., Engelholm, L. H., Grøntved, L., Junker, N., & Madsen, D. H. (2022) · Oncogene · doi:10.1038/s41388-021-02170-0 · Cited by 163
Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment
Xie, Q., Ding, J. P., & Chen, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.027 · Cited by 155
B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?
Lauss, M., Donia, M., Svane, I. M., & Jönsson, G. B. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1130 · Cited by 145
Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes
Zaitsev, A., Chelushkin, M., Dyikanov, D., Cheremushkin, I., Shpak, B., Nomie, K., Zyrin, V., Nuzhdina, E., Lozinsky, Y., Zotova, A., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.07.006 · Cited by 139
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression
Lin, J., Xu, A., Jin, J., Zhang, M., Lou, J., Qian, C., Zhu, J., Wang, Y., Yang, Z., Li, X., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.2024941 · Cited by 124
Inhibition of LDH-A by Oxamate Enhances the Efficacy of Anti-PD-1 Treatment in an NSCLC Humanized Mouse Model
Qiao, T., Xiong, Y., Feng, Y., Guo, W., Zhou, Y., Zhao, J., Jiang, T., Shi, C., & Han, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.632364 · Cited by 122
PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer
Wang, L., Guo, W., Zhikun, G., Yu, J., Tan, J., Simons, D. L., Hu, K., Liu, X., Zhou, Q., Zheng, Y.-Z., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101420 · Cited by 114
Recent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy
Chen, Q., Sun, T., & Jiang, C. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00622-6 · Cited by 115
Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling
Zugazagoitia, J., Gupta, S., Liu, Y., Fuhrman, K. A., Gettinger, S. N., Herbst, R. S., Schalper, K. A., & Rimm, D. L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0175 · Cited by 116
Self-citation
PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer
Ahmed, F. S., Gaule, P., McGuire, J., Patel, K., Blenman, K., Pusztai, L., & Rimm, D. L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1303 · Cited by 103
Self-citation
Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
Zhou, S., & Yang, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129465 · Cited by 98
Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation
Li, H., Luo, Q., Zhang, H., Ma, X., Gu, Z., Gong, Q., & Luo, K. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00437b · Cited by 93
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
Peranzoni, E., Ingangi, V., Masetto, E., Pinton, L., & Marigo, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01590 · Cited by 85
Tumor Immunology and Immunotherapy of Non-Small-Cell Lung CancerPreprint
Cascone, T., Fradette, J. J., Pradhan, M., & Gibbons, D. L. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037895 · Cited by 91
Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity
Zhong, W., Lu, Y., Han, X., Yang, J., Qin, Z., Zhang, W., Yu, Z., Wu, B., Liu, S., Xu, W., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113224 · Cited by 85
Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer
Aung, T. N., Monkman, J. H., Warrell, J., Vathiotis, I. A., Bates, K., Gavrielatou, N., Trontzas, I. P., Tan, C. W., Fernandez, A. I., Moutafi, M. K., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02351-7 · Cited by 100
Self-citation
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
Qu, J., Mei, Q., Liu, L., Cheng, T., Wang, P., Chen, L., & Zhou, J. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921992968 · Cited by 80
Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non–Small Cell Lung Cancer
Zugazagoitia, J., Liu, Y., Toki, M. I., McGuire, J., Ahmed, F. S., Henick, B. S., Gupta, R., Gettinger, S. N., Herbst, R. S., Schalper, K. A., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.014 · Cited by 75
Self-citation
Macrophage xCT deficiency drives immune activation and boosts responses to immune checkpoint blockade in lung cancer
Tang, B., Wang, Y., Xu, W., Zhu, J., Weng, Q., Chen, W., Fang, S., Yang, Y., Qiu, R., Chen, M., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216021 · Cited by 79
Insights into the Tumor Microenvironment—Components, Functions and Therapeutics
Baghy, K., Ladányi, A., Reszegi, A., & Kovalszky, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417536 · Cited by 79
Extracellular matrix stiffness and tumor-associated macrophage polarization: new fields affecting immune exclusion
Yu, K.-X., Yuan, W.-J., Wang, H.-Z., & Li, Y. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03675-9 · Cited by 88
Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 74
Self-citation
Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer
Zhang, L., Chen, Y., Wang, H., Xu, Z., Wang, Y., Li, S., Liu, J., Chen, Y., Luo, H., Wu, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002356 · Cited by 68
Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion
Wu, X., Cheng, Y. L., Mathew, M., Yoon, A. J., Schwartz, G. K., Bala, S., Taylor, A. M., & Momen‐Heravi, F. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01865-2 · Cited by 67
Mapping the Immune Landscape in Metastatic Melanoma Reveals Localized Cell–Cell Interactions That Predict Immunotherapy Response
Antoranz, A., Herck, Y. V., Bolognesi, M. M., Lynch, S. M., Rahman, A., Gallagher, W. M., Boecxstaens, V., Marine, J., Cattoretti, G., van den Oord, J. J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0363 · Cited by 63
DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion
Chen, B., Hu, J., Hu, X., Chen, H., Bao, R., Zhou, Y., Ye, Y., Zhan, M., Cai, W., Li, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29754-y · Cited by 61
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
Pan, Y., Fu, Y., Zeng, Y., Liu, X., Peng, Y., Hu, C., Deng, C., Qiu, Z., Zou, J. P., Liu, Y., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00355-7 · Cited by 57
Self-citation
Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy
Xu, S., Wang, C., Yang, L., Wu, J., Li, M., Xiao, P., Xu, Z., Xu, Y., & Wang, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1199631 · Cited by 59
Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer
Chen, Y., Gong, L., Cao, Y., Liu, Z., Wang, Y., Cheng, H. L. X. W., Feng, Y., Yao, S., Yin, Y., Wu, Z., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.058 · Cited by 61
A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis
Ma, Q., He, X., Zhang, B., Guo, F., Ou, X., Yang, Q., Shu, P., Chen, Y., Li, K., Gao, G., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01198-2 · Cited by 55
Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma
Okuyama, K., Naruse, T., & Yanamoto, S. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02691-4 · Cited by 55
ALKBH5 promotes non-small cell lung cancer progression and susceptibility to anti-PD-L1 therapy by modulating interactions between tumor and macrophages
Hua, X., Xu, Q., Wu, R., Sun, W., Gu, Y., Zhu, S., Liu, X., Lv, T., & Song, Y. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03073-0 · Cited by 53
Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases
Rodríguez‐Baena, F. J., Márquez-Galera, Á., Ballesteros-Martinez, P., Castillo, A., Diaz, E., Moreno‐Bueno, G., López‐Atalaya, J. P., & Sánchez‐Laorden, B. L. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.008 · Cited by 59
The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
Griessinger, C. M., Olafsen, T., Mascioni, A., Jiang, Z. K., Zamilpa, C., Jia, F., Torgov, M. Y., Romero, J. M., Marchioni, F., Satpayev, D., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3269 · Cited by 53
Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy
Fendl, B., Berghoff, A. S., Preusser, M., & Maier, B. (2023) · ESMO Open · doi:10.1016/j.esmoop.2022.100776 · Cited by 49
EGLIF-CAR-T Cells Secreting PD-1 Blocking Antibodies Significantly Mediate the Elimination of Gastric Cancer
Zhou, J.-T., Liu, J.-H., Song, T., Ma, B., Amidula, N., & Bai, C. (2020) · Cancer Management and Research · doi:10.2147/cmar.s260915 · Cited by 50
Macrophage secretory IL-1β promotes docetaxel resistance in head and neck squamous carcinoma via SOD2/CAT-ICAM1 signaling
Hsieh, C.-Y., Lin, C., Huang, Y.-W., Chen, J.-H., Tsou, Y., Chang, L., Fan, C., Lin, C., & Chang, W. (2022) · JCI Insight · doi:10.1172/jci.insight.157285 · Cited by 47
Modulation of miR-146b by N6-methyladenosine modification remodels tumor-associated macrophages and enhances anti-PD-1 therapy in colorectal cancer
He, S., Song, W., Cui, S., Li, J., Jiang, Y., Chen, X., & Peng, L. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00839-0 · Cited by 47
Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung
Moreo, E., Jarit-Cabanillas, A., Robles‐Vera, I., Uranga, S., Guerrero, C., Gómez, A. B., Mata-Martínez, P., Minute, L., Araujo‐Voces, M., Felgueres, M. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41768-8 · Cited by 47
A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival
Zhang, C., Sun, H., Su, J., Chen, Y., Zhang, S., Zheng, M.-Y., Li, Y., Huang, J., Zhang, C., Tai, Z., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.11.016 · Cited by 45
Multiplexed immunofluorescence identifies high stromal CD68+PD-L1+ macrophages as a predictor of improved survival in triple negative breast cancer
Wang, J., Browne, L. H., Šlapetová, I., Shang, F., Lee, K., Lynch, J., Beretov, J., Whan, R. M., Graham, P., & Millar, E. K. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-01116-6 · Cited by 47
Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes
Ni, Y., Tsang, J. Y., Shao, Y., Poon, I. K., Tam, F. K. Y., Shea, K.-H., & Tse, G. M.-K. (2022) · The Oncologist · doi:10.1093/oncolo/oyab063 · Cited by 45
TMP195 Exerts Antitumor Effects on Colorectal Cancer by Promoting M1 Macrophages Polarization
Han, Y., Sun, J., Yang, Y., Liu, Y., Lou, J., Pan, H., Yao, J., & Han, W. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73264 · Cited by 45
Self-citation
Emerging diversity in extracellular vesicles and their roles in cancer
Sohal, I. S., & Kasinski, A. L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1167717 · Cited by 44
Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer
Li, Y., Sharma, A., & Schmidt‐Wolf, I. G. H. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01926-4 · Cited by 48
Multi‐omic and spatial dissection of immunotherapy response groups in non‐small cell lung cancer
Monkman, J. H., Kim, H., Mayer, A. T., Mehdi, A. M., Matigian, N., Cumberbatch, M., Bhagat, M., Ladwa, R., Mueller, S. N., Adams, M. N., et al. (2023) · Immunology · doi:10.1111/imm.13646 · Cited by 44
GIS in Teacher Education - Facilitating GIS Applications in Secondary School Geography.
Johansson, T. (2003) · Cited by 42
Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma
Liu, X., Zhou, J., Wu, H., Chen, S., Zhang, L., Tang, W., Duan, L., Wang, Y., McCabe, E., Hu, M., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.012 · Cited by 41
Comprehensive single-cell analysis demonstrates radiotherapy-induced infiltration of macrophages expressing immunosuppressive genes into tumor in esophageal squamous cell carcinoma
Oyoshi, H., Du, J., Sakai, S. A., Yamashita, R., Okumura, M., Motegi, A., Hojo, H., Nakamura, M., Hirata, H., Sunakawa, H., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh9069 · Cited by 42
Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages
Sato, T., Sugiyama, D., Koseki, J., Kojima, Y., Hattori, S., Sone, K., Nishinakamura, H., Ishikawa, T., Ishikawa, Y., Kato, T., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.178146 · Cited by 43
Advanced insights on tumor-associated macrophages revealed by single-cell RNA sequencing: The intratumor heterogeneity, functional phenotypes, and cellular interactions
Yang, S., Wang, M., Hua, Y., Li, J., Zheng, H., Cui, M., Huang, N., Liu, Q., & Liao, Q. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216610 · Cited by 43
Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients
Brück, O. E., Lee, M. H., Turkki, R., Uski, I., Penttilä, P., Paavolainen, L., Kovanen, P. E., Järvinen, P., Bono, P., Pellinen, T. S., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00864-0 · Cited by 43
Biomarkers for predicting the efficacy of immune checkpoint inhibitors
Wang, C., Wang, H.-N., & Wang, L. (2022) · Journal of Cancer · doi:10.7150/jca.65012 · Cited by 39
Tumor-associated macrophages in lymphoma: From mechanisms to therapy
Xiong, X., Xie, X., Wang, Z., Zhang, Y., & Wang, L. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109235 · Cited by 40
Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non–Small Cell Lung Cancer
Datar, I. J., Hauc, S. C., Desai, S., Gianino, N., Henick, B. S., Liu, Y., Syrigos, K., Rimm, D. L., Kavathas, P., Ferrone, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3655 · Cited by 39
Self-citation
Immune parameters associated with survival in metaplastic breast cancer
Chao, X., Liu, L., Sun, P., Yang, X., Li, M., Luo, R., Huang, Y., He, J., & Yun, J. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01330-6 · Cited by 38
The evolving landscape of predictive biomarkers in immuno‐oncology with a focus on spatial technologies
Sadeghirad, H., Bazaz, S. R., Monkman, J. H., Warkiani, M. E., Rezaei, N., O'Byrne, K. J., & Kulasinghe, A. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1215 · Cited by 37
Assessing dynamic metabolic heterogeneity in non-small cell lung cancer patients via ultra-high sensitivity total-body [18F]FDG PET/CT imaging: quantitative analysis of [18F]FDG uptake in primary tumors and metastatic lymph nodes
Wang, D., Zhang, X., Liu, H., Qiu, B., Liu, S., Zheng, C., Fu, J., Mo, Y., Chen, N., Zhou, R., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05904-8 · Cited by 41
Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images
Patkar, S., Chen, A., Basnet, A., Bixby, A., Rajendran, R., Chernet, R., Faso, S., Kumar, P. A., Desai, D., El-Zammar, O., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00765-w · Cited by 41
“A previous study by Liu et al highlighted an example of this complexity, revealing in NSCLC patients treated with ICI that only high PD-L1 expression in macrophages was correlated with better overall survival, while high PD-L1 expression in tumor or stromal cells was not 39 .”
One cisplatin dose provides durable stimulation of anti-tumor immunity and alleviates anti-PD-1 resistance in an intraductal model for triple-negative breast cancer
Steenbrugge, J., Bellemans, J., Elst, N. V., Demeyere, K., Vliegher, J. D., Perera, T. P. S., Wever, O. D., Broeck, W. V. D., Spiegelaere, W. D., Sanders, N. N., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2103277 · Cited by 37
Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer
Polverino, F., Mirra, D., Yang, C. X., Esposito, R., Spaziano, G., Rojas, J., Sgambato, M., Piegari, E., Cozzolino, A., Cione, E., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-26650-9 · Cited by 36
Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response
Hajiran, A. J., Chakiryan, N. H., Aydın, A. M., Zemp, L. W., Nguyen, J. V., Laborde, J. M., Chahoud, J., Spiess, P. E., Zaman, S., Falasiri, S. S. A., et al. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13567 · Cited by 36
Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma
Li, L., Lu, G., Liu, Y., Gong, L., Zheng, X. Y., Zheng, H., Gu, W., & Yang, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.658690 · Cited by 39
Self-citation
Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages
Reis-Sobreiro, M., da Mota, A. T., Jardim, C., & Serre, K. (2021) · Cells · doi:10.3390/cells10092364 · Cited by 44
Spatially multiplexed RNA in situ hybridization to reveal tumor heterogeneity
von Voithenberg, L. V., Khartchenko, A. F., Huber, D., Schraml, P., & Kaigala, G. V. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1151 · Cited by 35
Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment
Koo, J., Hayashi, M., Verneris, M. R., & Lee‐Sherick, A. B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.581107 · Cited by 34
Overexpression of transposable elements is associated with immune evasion and poor outcome in colorectal cancer
Zhu, X., Fang, H., Gladysz, K., Barbour, J. A., & Wong, J. W. H. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.003 · Cited by 35
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 38
Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy
Yu, X., Zhai, X., Wu, J., Feng, Q., Hu, C., Zhu, L., & Zhou, Q. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166881 · Cited by 35
Tumor-associated macrophages as a potential therapeutic target in thyroid cancers
Zhu, L., Li, X. J., Gangadaran, P., Jing, X., & Ahn, B. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03549-6 · Cited by 35
PAD4 controls tumor immunity via restraining the MHC class II machinery in macrophages
Pitter, M. R., Kryczek, I., Zhang, H., Nagarsheth, N., Xia, H., Wu, Z., Tian, Y., Okła, K., Liao, P., Wang, W., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113942 · Cited by 34
Classification of Non-Small Cell Lung Cancer’s Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade
Chi, A., He, X., Hou, L., Nguyen, N. P., Zhu, G., Cameron, R. B., & Lee, J. M. (2021) · Cancers · doi:10.3390/cancers13122924 · Cited by 36
Dynamic polarization of tumor-associated macrophages and their interaction with intratumoral T cells in an inflamed tumor microenvironment: from mechanistic insights to therapeutic opportunities
Han, J., Dong, L., Wu, M., & Ma, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160340 · Cited by 36
Spatial proteomic profiling elucidates immune determinants of neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma
Wu, C., Zhang, G., Wang, L., Hu, J., Ju, Z., Tao, H., Li, Q., Li, J., Zhang, W., Sheng, J., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03123-z · Cited by 35
Response to immune checkpoint blockade improved in pre-clinical model of breast cancer after bariatric surgery
Sipe, L. M., Chaib, M., Korba, E. B., Jo, H., Lovely, M. C., Counts, B. R., Tanveer, U. A., Holt, J. R., Clements, J. C., John, N. A., et al. (2022) · eLife · doi:10.7554/elife.79143 · Cited by 32
Tumour-associated macrophages: versatile players in the tumour microenvironment
Ji, Z. Z., Chan, M. K., Chan, A. S. W., Leung, K. T., Jiang, X., To, K., Wu, Y., & Tang, P. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1261749 · Cited by 33
Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance
Fu, Y., Guo, X., Sun, L., Cui, T., Wu, C., Wang, J., Liu, Y., & Liu, L. (2024) · eLife · doi:10.7554/elife.95009 · Cited by 31
Self-citation
Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer
Albrecht, T., Brinkmann, F., Albrecht, M. C., Lonsdorf, A. S., Mehrabi, A., Hoffmann, K., Kulu, Y., Charbel, A., Vogel, M. N., Rupp, C., et al. (2021) · Cancers · doi:10.3390/cancers13071682 · Cited by 31
SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response
Tanagala, K. K. K., Morin‐Baxter, J., Carvajal, R. D., Cheema, M., Dubey, S., Nakagawa, H., Yoon, A. J., Cheng, Y. L., Taylor, A. M., Nickerson, J. A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005088 · Cited by 31
Role of Heterogeneous Nuclear Ribonucleoproteins in the Cancer-Immune Landscape
Sudhakaran, M., & Doseff, A. I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065086 · Cited by 31
Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer
Shen, M., Qi, R., Ren, J., Lv, D., & Yang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.780655 · Cited by 31
Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer
Rochigneux, P., Lisberg, A. E., Garcia, A. J., Granjeaud, S., Madroszyk, A., Fattori, S., Gonçalvès, A., Devillier, R., Maby, P., Salem, N., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1386 · Cited by 30
Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Mishra, A., Kumar, D., Gupta, K., Lofland, G., Sharma, A., Banka, D. S., Hobbs, R. F., Dannals, R. F., Rowe, S. P., Gabrielson, E. W., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1931 · Cited by 29
LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors
He, Z., Feng, W., Wang, Y., Shi, L., Gong, Y., Shi, Y., Shen, S., & Huang, H. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-39 · Cited by 28

Authors: Liu, Y., Zugazagoitia, J., Ahmed, F. S., Henick, B. S., Gettinger, S. N., Herbst, R. S., Schalper, K. A., & Rimm, D. L.
Affiliations: Yale University (US)
Columbia University Irving Medical Center (US)
Corresponding author: Rimm, David L.
ORCID: Liu, Yuting
Zugazagoitia, Jon
Ahmed, Fahad Shabbir
Henick, Brian S.
Gettinger, Scott N.
Herbst, Roy S.
Schalper, Kurt A.
Rimm, David L.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2020-02-14
Volume: 26
Issue: 4
Pages: 970-977
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-19-1040
PMC: PMC7024671
OpenAlex: W2980933209
Cited by: 322
References: 34
Citations by year: 2026: 23 · 2025: 28 · 2024: 65 · 2023: 59 · 2022: 64 · 2021: 50 · 2020: 25
FWCI: 14.73
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Yale SPORE in Lung Cancer (P50-CA196530)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords: PD-L1, tumor-associated macrophages, PD-1 pathway blockade, non-small cell lung cancer, pembrolizumab, nivolumab, atezolizumab, predictive biomarkers, CD8+ T cells, tumor immune microenvironment, overall survival
MeSH terms: Antineoplastic Agents, Immunological, Aged, Carcinoma, Non-Small-Cell Lung, Female, Humans, Killer Cells, Natural, Lung Neoplasms, Macrophages, Male, Neoplasm Staging, Retrospective Studies, Biomarkers, Tumor, Survival Rate, CD8-Positive T-Lymphocytes, B7-H1 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks